4D Molecular Therapeutics reported a new round of equity grants this week. On August 11, the compensation committee of the board of directors approved 35,200 Restricted Stock Units for five new non-executive employees.
These grants are issued under the company’s 2025 Employment Inducement Award Plan. This move aligns with Nasdaq Rule 5635(c)(4), which allows for equity awards as a condition of employment for new staff members.
4DMT is a biotechnology firm focused on disease-targeted therapeutics. Their current pipeline includes 4D-150, a candidate for wet age-related macular degeneration and diabetic macular edema, as well as 4D-710 for cystic fibrosis treatment. These programs remain in clinical and preclinical development phases.
The company continues to work on its delivery vectors and therapeutic candidates while maintaining its operational structure. Investors can monitor these updates as the firm progresses through its clinical trials and regulatory requirements.